BOLT (Bolt Biotherapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Bolt Biotherapeutics, Inc. Common Stock (BOLT) is a publicly traded Healthcare sector company. As of May 21, 2026, BOLT trades at $4.63 with a market cap of $8.38M and a P/E ratio of -0.28. BOLT moved -6.25% today. Year to date, BOLT is -18.55%; over the trailing twelve months it is -30.09%. Its 52-week range spans $3.91 to $14.36. Analyst consensus is buy with an average price target of $30.33. Rallies surfaces BOLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate BOLT?

3 analysts cover BOLT: 0 strong buy, 2 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $30.33.

BOLT Key Metrics

Key financial metrics for BOLT
MetricValue
Price$4.63
Market Cap$8.38M
P/E Ratio-0.28
EPS$-16.40
Dividend Yield0.00%
52-Week High$14.36
52-Week Low$3.91
Volume0
Avg Volume0
Revenue (TTM)$6.50M
Net Income$-29.58M
Gross Margin0.00%

BOLT Analyst Consensus

3 analysts cover BOLT: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.33.

Latest BOLT News

Recent BOLT Insider Trades

  • Quinn William P. bought 125 (~$575.875) on Dec 5, 2025.
  • Nemec Sarah bought 125 (~$575.875) on Dec 5, 2025.
  • Nemec Sarah bought 125 (~$686.5) on Jun 6, 2025.

Common questions about BOLT

What do analysts rate BOLT?
3 analysts cover BOLT: 0 strong buy, 2 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $30.33.
Does Rallies show BOLT price targets?
Yes. Rallies tracks BOLT analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is BOLT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BOLT. It does not provide personalized investment advice.
BOLT

BOLT